The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
Open accessAbstract
OBJECTIVE: This study is a pharmacogenetic clinical trial designed to clarify whether the N-acetyltransferase 2 gene (NAT2) genotype-guided dosing of isoniazid improves the tolerability and efficacy of the 6-month four-drug standard regimen for newly diagnosed pulmonary tuberculosis. METHODS: In a multicenter, parallel, randomized, and controlled trial with a PROBE design, patients were assigned to either conventional standard treatment (STD-treatment: approx. 5 mg/kg of isoniazid for all) or NAT2 genotype-guided treatment (PGx-treatment: approx. 7.5 mg/kg for patients homozygous for NAT2 4: rapid acetylators; 5 mg/kg, patients heterozygous for NAT2 4: intermediate acetylators; 2.5 mg/kg, patients without NAT2 4: slow acetylators). The primary outcome included incidences of 1) isoniazid-related liver injury (INH-DILI) during the first 8 weeks of therapy, and 2) early treatment failure as indicated by a persistent positive culture or no improvement in chest radiographs at the 8th week. RESULTS: One hundred and seventy-two Japanese patients (slow acetylators, 9.3 %; rapid acetylators, 53.5 %) were enrolled in this trial. In the intention-to-treat (ITT) analysis, INH-DILI occurred in 78 % of the slow acetylators in the STD-treatment, while none of the slow acetylators in the PGx-treatment experienced either INH-DILI or early treatment failure. Among the rapid acetylators, early treatment failure was observed with a significantly lower incidence rate in the PGx-treatment than in the STD-treatment (15.0 % vs. 38 %). Thus, the NAT2 genotype-guided regimen resulted in much lower incidences of unfavorable events, INH-DILI or early treatment failure, than the conventional standard regimen. CONCLUSION: Our results clearly indicate a great potential of the NAT2 genotype-guided dosing stratification of isoniazid in chemotherapy for tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., & Menzies, D. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-626oc · Cited by 840
Genetic Control of Isoniazid Metabolism in Man
Evans, D. A. P., Manley, K. A., & McKusick, V. A. (1960) · BMJ · doi:10.1136/bmj.2.5197.485 · Cited by 784
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Jindani, A., Aber, V. R., Edwards, E. A., & Mitchison, D. A. (1980) · PubMed · doi:10.1164/arrd.1980.121.6.939 · Cited by 487
Toxic Hepatitis with Isoniazid and Rifampin
Steele, M. A., Burk, R. F., & DesPrez, R. M. (1991) · Chest · doi:10.1378/chest.99.2.465 · Cited by 437
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Lai, S.-L., Yang, S.-Y., Chang, F.-Y., & Lee, S.-D. (2002) · Hepatology · doi:10.1053/jhep.2002.32102 · Cited by 432
Cascorbi, I., Drakoulis, N., Brockmöller, J., Maurer, A., Sperling, K., & Roots, I. (1995) · Europe PMC (PubMed Central) · Cited by 328
Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days
Jindani, A., Doré, C. J., & Mitchison, D. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1125oc · Cited by 321
Ohno, M., Yamaguchi, I., Yamamoto, I., Fukuda, T., Yokota, S., Maekura, R., Ito, M., Yamamoto, Y., Ogura, T., Maeda, K., et al. (2000) · PubMed · Cited by 251
Self-citation
Cited by
Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
Alsultan, A., & Peloquin, C. A. (2014) · Drugs · doi:10.1007/s40265-014-0222-8 · Cited by 444
Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis
Unissa, A. N., Subbian, S., Hanna, L. E., & Selvakumar, N. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.09.004 · Cited by 300
Isoniazid metabolism and hepatotoxicity
Wang, P., Pradhan, K., Zhong, X.-B., & Ma, X. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.07.014 · Cited by 257
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
McDonagh, E. M., Boukouvala, S., Aklillu, E., Hein, D. W., Altman, R. B., & Klein, T. E. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000062 · Cited by 146
Nicoletti, P., Devarbhavi, H., Goel, A., Venkatesan, R., Eapen, C. E., Grove, J. I., Zafer, S., Bjornsson, E., Lucena, M. I., Andrade, R. J., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2100 · Cited by 61
“Autoimmune(-Like)” drug and herb induced liver injury: new insights into molecular pathogenesis
Sebode, M., Schulz, L., & Lohse, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091954 · Cited by 47
Aklillu, E., Carrillo, J. A., Makonnen, E., Bertilsson, L., & Djordjevic, N. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2448-y · Cited by 28
Metadata
- Authors
- Pharmacogenetics-based tuberculosis therapy research group, Azuma, J., Ohno, M., Kubota, R., Yokota, S., Nagai, T., Tsuyuguchi, K., Okuda, Y., Takashima, T., Kamimura, S., Fujio, Y., & Kawase, I.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2012-11-14
- Volume
- 69
- Issue
- 5
- Pages
- 1091-1101
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2170012142
- Cited by
- 278
- References
- 21
- FWCI
- 11.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.